Skip to content

Pulmonx Corporation LUNG Professional Service Fees Payable

Professional Service Fees Payable at other companies

LivaNova logo
LivaNovaLIVN

Other financials

Income statement

See full
Revenue$20.6M-8.7%
Gross profit$16.0M-1.8%
Operating income-$13.0M+11.0%
Net income-$13.7M+5.5%
EPS (diluted)-$0.33+8.3%

Balance sheet

See full
Cash & equivalents$61.0M-2.4%
Total debt$56.3M-1.2%
Total equity$45.8M-41.1%
Total assets$120.0M-20.4%

Cash flow

See full
Operating cash flow-$10.1M+23.6%
CapEx$9.0K-97.0%
Free cash flow-$10.1M+25.3%

Valuation

See full
Market cap$54.91M-43.7%
Enterprise value$50.17M-39.2%
P/S0.6×-0.5×

Profitability

See full
Gross margin75.5%+2.0pp
Operating margin-58.8%-5.8pp
Net margin-60.1%-4.4pp
FCF margin-33.2%-4.4pp

Returns & leverage

See full
Return on equity-86.2%+62.6pp
Debt / equity1.2×+0.5×
Current ratio4.9×-0.1×

Where this comes from

Reported directly by Pulmonx Corporation in its filing.

Tagged under the XBRL concept us-gaap:AccruedProfessionalFeesCurrent.

The official record: Pulmonx Corporation’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pulmonx Corporation's professional service fees payable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pulmonx Corporation's professional service fees payable?
Pulmonx Corporation (LUNG) reported professional service fees payable of $3.69M in Q1 2026.
How has Pulmonx Corporation's professional service fees payable changed year-over-year?
Pulmonx Corporation's professional service fees payable increased by 48.5% year-over-year, from $2.48M to $3.69M.
What is the long-term trend for Pulmonx Corporation's professional service fees payable?
Over 5 years (2020 to 2025), Pulmonx Corporation's professional service fees payable has grown at a 18.1% compound annual growth rate (CAGR), from $1.31M to $3.02M.